<bill session="113" type="hr" number="161" updated="2014-08-17T22:21:52-04:00">
  <state datetime="2013-04-15">REFERRED</state>
  <status>
    <introduced datetime="2013-04-15"/>
  </status>
  <introduced datetime="2013-04-15"/>
  <titles>
    <title type="official" as="introduced">Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.</title>
  </titles>
  <sponsor thomas_id="00977"/>
  <cosponsors>
    <cosponsor thomas_id="01460" joined="2013-04-15"/>
    <cosponsor thomas_id="02041" joined="2013-04-15"/>
    <cosponsor thomas_id="02025" joined="2013-04-15"/>
    <cosponsor thomas_id="01686" joined="2013-04-15"/>
    <cosponsor thomas_id="00940" joined="2013-04-15"/>
    <cosponsor thomas_id="01535" joined="2013-04-15"/>
    <cosponsor thomas_id="01238" joined="2013-04-15"/>
  </cosponsors>
  <actions>
    <action datetime="2013-04-15" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2013-04-19">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee subcommittee="Health" code="HSIF14" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="sr" session="113" relation="unknown" number="97"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary>4/15/2013--Introduced.
Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.</summary>
</bill>
